ERBB2 and gastric cancer: Additionally, the objective response rate of HER2-targeted therapies to those patients with HER2-overexpressed GC was ranged from 26.3 to 57.0% (15, 16), suggesting that intra-tumoral HER2 expression cannot fully correlate with clinical response to HER2-based targeted therapies.